Tirzepatide and prediabetes: slowing progression to type 2 diabetes
Beyond weight, a longer look at whether tirzepatide can delay diabetes itself.
A window to act
Prediabetes — blood glucose above normal but below the diabetes threshold — carries elevated risk of progressing to type 2 diabetes. Because weight loss reduces that risk, a powerful weight-loss therapy raises a natural question: can it delay or prevent diabetes onset?
Longer follow-up
The SURMOUNT-1 trial included a substantial subgroup with prediabetes, who were followed in a longer extension (well beyond the initial 72 weeks). The analysis reported that tirzepatide reduced progression to type 2 diabetes compared with placebo, with weight loss largely sustained over the extended period.
Prevention vs delay
Findings like these suggest tirzepatide can at least delay diabetes onset in high-risk people while treatment continues. As with weight, benefits depend on ongoing treatment — and the regain biology covered elsewhere means stopping could change the trajectory. Long-term prevention claims require long-term data.
Shifting the goal
If sustained, a reduction in diabetes incidence would extend tirzepatide's value beyond weight and glucose control toward disease prevention — a meaningful public-health framing, though decisions remain individual and clinician-led.
Not advice
This summarizes a trial extension, not a recommendation. Diabetes prevention strategies should be individualized. Compounded tirzepatide is not FDA-approved.
Prevention requires sustained treatment
The prediabetes findings are encouraging, but they come with the same chronic-disease caveat that runs through the obesity evidence: benefits depend on continued treatment. Reduced progression to type 2 diabetes was observed while participants remained on tirzepatide, and the weight-regain biology seen when the drug stops suggests the protective effect could diminish after discontinuation — so this is better described as delaying onset during treatment than as a permanent cure for diabetes risk. That still has real value: delaying diabetes can postpone or reduce complications and buy time for other interventions. It also raises questions the data are still answering, such as how long the benefit persists, who benefits most, and how this compares with established prevention approaches like intensive lifestyle programs, which themselves reduce diabetes incidence. For an individual at high risk, the decision to use medication for prevention weighs these factors, side effects, duration and cost — a nuanced, clinician-led choice rather than an automatic one. As ever, this is research evidence informing care, not a directive.
Primary sources
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
- Garvey WT, Frías JP, Jastreboff AM, et al. Tirzepatide once weekly in people with type 2 diabetes and obesity (SURMOUNT-2). Lancet. 2023;402(10402):613-626.
- U.S. Food and Drug Administration. Mounjaro and Zepbound (tirzepatide) prescribing information. Eli Lilly and Company.
Citations are provided for educational reference. This article summarizes published research in plain language and is not medical advice. Always consult a licensed clinician.
Common questions
Can tirzepatide prevent type 2 diabetes?
A SURMOUNT-1 extension reported reduced progression to type 2 diabetes versus placebo in people with obesity and prediabetes, suggesting it can at least delay onset while treatment continues.
Does the benefit last after stopping?
Long-term prevention depends on continued treatment; weight-regain biology suggests stopping could change the trajectory. Long-term data are needed.
Is tirzepatide approved to prevent diabetes?
This is research evidence; approved uses and suitability are clinical questions to discuss with your clinician.